---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-138874"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:23:47.877050+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Q1 2024: $223.8M cash, no CRS/ICANS in CABA-201 trials; clinical data at EULAR June

## Summary
- Cash, cash equivalents and short-term investments of $223.8M as of March 31, 2024, down from $241.2M Dec 31, 2023; runway into H1 2026.
- R&D expense $22.0M (vs $12.4M YoY); G&A $6.1M (vs $4.5M YoY).
- No CRS or ICANS of any grade observed in first patients dosed in RESET-Myositis and RESET-SLE trials.
- Initial clinical data from first patients in myositis and SLE to be presented at EULAR 2024 Congress in June.
- FDA granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations for CABA-201 in myositis; Fast Track and Orphan for SSc.

## SEC filing metadata
- accession: 0001193125-24-138874
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312524138874/0001193125-24-138874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312524138874/d106913d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-138874
- JSON: https://secwatch.observer/filing/0001193125-24-138874.json
- Plain text: https://secwatch.observer/filing/0001193125-24-138874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.